Fig. 2From: Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE studyEdoxaban medication status. Starting edoxaban daily dose according the presence of the following dosage adjustment factors: body weight ≤ 60 kg, creatinine clearance ≤50 mL/min, and concomitant use of P-glycoprotein inhibitors (e.g., quinidine)Back to article page